fluzoparib: Clinical Trials

10 trials of fluzoparib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown, 2 active not recruiting, 2 recruiting, 1 completed. 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 310Unknown 3, Active not recruiting 2, Recruiting 2, Completed 1, Not yet recruiting 1, Terminated 1

Follow fluzoparib: new trials by email Literature Review of fluzoparib trials Research Report on fluzoparib

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
Fluzoparib Capsules, Apatinib Mesylate Tablets - Ovarian Cancer
Phase 3Not yet recruitingThe First Affiliated Hospital of Xiamen University372024-12-012024-01-03
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
Fluzoparib, Apatinib Mesylate - Epithelial Ovarian Cancer, Efficacy
Phase 3UnknownAnhui Provincial Hospital512024-10-012024-08-06
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Fluzoparib, Dalpiciclib, Fulvestrant/AI - Breast Cancer Metastatic
Phase 3Active not recruitingZhimin Shao3072024-09-012024-09-25
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Fluzoparib, Apatinib Mesylate, Capecitabine tablets - Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
Phase 3RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2002024-06-122025-08-15
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fluzoparib, Anastrozole, Letrozole - Breast Cancer
Phase 3RecruitingFudan University7662023-06-012024-02-08
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo, Abiraterone acetate and Prednisone - Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 3Active not recruitingJiangsu HengRui Medicine Co., Ltd.4962021-03-182024-12-31
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Fluzoparib, Placebo - Metastatic Pancreatic Cancer
Phase 3TerminatedJiangsu HengRui Medicine Co., Ltd.52020-08-192024-03-28
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Fluzoparib; Apatinib, Fluzoparib, Physician's choice chemotherapy - Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.4742020-07-132020-08-10
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Fluzoparib; Apatinib, Fluzoparib, Placebo - Ovarian Cancer, Fallopian Tube Cancer
Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.6902020-06-022022-04-25
A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients
Fluzoparib capsules, Placebo capsules - Ovarian Cancer
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.2522019-04-302025-07-03

Conditions studied

Ovarian Neoplasms (3)  ·  Breast Neoplasms (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Fallopian Tube Neoplasms (1)  ·  Pancreatic Neoplasms (1)

Sponsors

Jiangsu HengRui Medicine Co., Ltd. (5)  ·  Anhui Provincial Hospital (1)  ·  Fudan University (1)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)  ·  The First Affiliated Hospital of Xiamen University (1)  ·  Zhimin Shao (1)

Countries

China (8)  ·  Australia (1)  ·  Belgium (1)  ·  Czechia (1)  ·  France (1)  ·  Hungary (1)  ·  Poland (1)  ·  Russia (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Jianli Zhao (1)  ·  Lingying Wu (1)  ·  Ying Zhou, MD (1)  ·  Yupei Zhao, Ph.D (1)

Results publications

PMID 35404684, PMID 41308673